Verrica Pharmaceuticals Inc.
VRCA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 12.9% | 269.4% | 899.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 92.3% | 97.3% | 87.7% | -81.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | -$0 | -$0 |
| % Margin | 11.3% | 11.9% | -236.4% | -3,316.9% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -1.9% | 1.6% | -283.3% | -4,709.9% |
| EPS | -0.03 | 0.022 | -1.03 | -2.41 |
| % Growth | -239.5% | 102.1% | 57.3% | – |
| EPS Diluted | -0.03 | 0.022 | -1.03 | -2.41 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 14% | 19.9% | -213.2% | -3,953.5% |